Esophageal pH monitoring with the BRAVO capsule: Experience in a single tertiary medical center

José Cabrera, Miriam Davis, Debbie Horn, Marian Pfefferkorn, Joseph Croffie

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aim: The aim of the present study was to report the global experience with placement, complication rate, and recording of esophageal pH using the BRAVO capsule at our institution. Patients and Methods: We recorded the rate of any technical problems and complications during placement in all of the patients (ages 4-22 years) who received this device during a 2-year period. All of the patients undergoing esophagogastroduodenoscopy with the placement of BRAVO pH capsule were included in this analysis. We also examined the pH data recorded on days 1 and 2 for significant day-to-day variability during 2 days of pH monitoring. Results: Two hundred eighty-nine BRAVO pH probes were placed from January 1, 2006 to December 31, 2008. At least 1 day of data was obtained in 278 patients (96.2%). Two days of data were obtained in 274 patients (94.8%). Of all of the reported complications, 1% occurred before deployment of the capsule, 4% occurred during deployment of the capsule, and 9% occurred after successful deployment of the capsule. One patient experienced a superficial esophageal tear that was associated with failure of the capsule to release from the delivery system. No patient requested removal of the capsule and all of the capsules detached within 14 days. In 9.12% of our patients, reflux index was normal on day 1 and abnormal on day 2. There was no statistically significant difference between reflux index recorded on day 1 versus day 2 (P=0.686). Conclusions: The BRAVO pH capsule is easy to place, safe, and well tolerated by children. Performing a 48-hour study detected abnormal reflux in an additional 9% of our patients.

Original languageEnglish
Pages (from-to)404-408
Number of pages5
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume53
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Esophageal pH Monitoring
Capsules
Digestive System Endoscopy
Tears
Equipment and Supplies

Keywords

  • BRAVO capsule
  • children
  • esophageal pH

ASJC Scopus subject areas

  • Gastroenterology
  • Pediatrics, Perinatology, and Child Health

Cite this

Esophageal pH monitoring with the BRAVO capsule : Experience in a single tertiary medical center. / Cabrera, José; Davis, Miriam; Horn, Debbie; Pfefferkorn, Marian; Croffie, Joseph.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 53, No. 4, 10.2011, p. 404-408.

Research output: Contribution to journalArticle

@article{4fcc1c2442314e989b7171edf583f052,
title = "Esophageal pH monitoring with the BRAVO capsule: Experience in a single tertiary medical center",
abstract = "Aim: The aim of the present study was to report the global experience with placement, complication rate, and recording of esophageal pH using the BRAVO capsule at our institution. Patients and Methods: We recorded the rate of any technical problems and complications during placement in all of the patients (ages 4-22 years) who received this device during a 2-year period. All of the patients undergoing esophagogastroduodenoscopy with the placement of BRAVO pH capsule were included in this analysis. We also examined the pH data recorded on days 1 and 2 for significant day-to-day variability during 2 days of pH monitoring. Results: Two hundred eighty-nine BRAVO pH probes were placed from January 1, 2006 to December 31, 2008. At least 1 day of data was obtained in 278 patients (96.2{\%}). Two days of data were obtained in 274 patients (94.8{\%}). Of all of the reported complications, 1{\%} occurred before deployment of the capsule, 4{\%} occurred during deployment of the capsule, and 9{\%} occurred after successful deployment of the capsule. One patient experienced a superficial esophageal tear that was associated with failure of the capsule to release from the delivery system. No patient requested removal of the capsule and all of the capsules detached within 14 days. In 9.12{\%} of our patients, reflux index was normal on day 1 and abnormal on day 2. There was no statistically significant difference between reflux index recorded on day 1 versus day 2 (P=0.686). Conclusions: The BRAVO pH capsule is easy to place, safe, and well tolerated by children. Performing a 48-hour study detected abnormal reflux in an additional 9{\%} of our patients.",
keywords = "BRAVO capsule, children, esophageal pH",
author = "Jos{\'e} Cabrera and Miriam Davis and Debbie Horn and Marian Pfefferkorn and Joseph Croffie",
year = "2011",
month = "10",
doi = "10.1097/MPG.0b013e3182203caa",
language = "English",
volume = "53",
pages = "404--408",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Esophageal pH monitoring with the BRAVO capsule

T2 - Experience in a single tertiary medical center

AU - Cabrera, José

AU - Davis, Miriam

AU - Horn, Debbie

AU - Pfefferkorn, Marian

AU - Croffie, Joseph

PY - 2011/10

Y1 - 2011/10

N2 - Aim: The aim of the present study was to report the global experience with placement, complication rate, and recording of esophageal pH using the BRAVO capsule at our institution. Patients and Methods: We recorded the rate of any technical problems and complications during placement in all of the patients (ages 4-22 years) who received this device during a 2-year period. All of the patients undergoing esophagogastroduodenoscopy with the placement of BRAVO pH capsule were included in this analysis. We also examined the pH data recorded on days 1 and 2 for significant day-to-day variability during 2 days of pH monitoring. Results: Two hundred eighty-nine BRAVO pH probes were placed from January 1, 2006 to December 31, 2008. At least 1 day of data was obtained in 278 patients (96.2%). Two days of data were obtained in 274 patients (94.8%). Of all of the reported complications, 1% occurred before deployment of the capsule, 4% occurred during deployment of the capsule, and 9% occurred after successful deployment of the capsule. One patient experienced a superficial esophageal tear that was associated with failure of the capsule to release from the delivery system. No patient requested removal of the capsule and all of the capsules detached within 14 days. In 9.12% of our patients, reflux index was normal on day 1 and abnormal on day 2. There was no statistically significant difference between reflux index recorded on day 1 versus day 2 (P=0.686). Conclusions: The BRAVO pH capsule is easy to place, safe, and well tolerated by children. Performing a 48-hour study detected abnormal reflux in an additional 9% of our patients.

AB - Aim: The aim of the present study was to report the global experience with placement, complication rate, and recording of esophageal pH using the BRAVO capsule at our institution. Patients and Methods: We recorded the rate of any technical problems and complications during placement in all of the patients (ages 4-22 years) who received this device during a 2-year period. All of the patients undergoing esophagogastroduodenoscopy with the placement of BRAVO pH capsule were included in this analysis. We also examined the pH data recorded on days 1 and 2 for significant day-to-day variability during 2 days of pH monitoring. Results: Two hundred eighty-nine BRAVO pH probes were placed from January 1, 2006 to December 31, 2008. At least 1 day of data was obtained in 278 patients (96.2%). Two days of data were obtained in 274 patients (94.8%). Of all of the reported complications, 1% occurred before deployment of the capsule, 4% occurred during deployment of the capsule, and 9% occurred after successful deployment of the capsule. One patient experienced a superficial esophageal tear that was associated with failure of the capsule to release from the delivery system. No patient requested removal of the capsule and all of the capsules detached within 14 days. In 9.12% of our patients, reflux index was normal on day 1 and abnormal on day 2. There was no statistically significant difference between reflux index recorded on day 1 versus day 2 (P=0.686). Conclusions: The BRAVO pH capsule is easy to place, safe, and well tolerated by children. Performing a 48-hour study detected abnormal reflux in an additional 9% of our patients.

KW - BRAVO capsule

KW - children

KW - esophageal pH

UR - http://www.scopus.com/inward/record.url?scp=80053649658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053649658&partnerID=8YFLogxK

U2 - 10.1097/MPG.0b013e3182203caa

DO - 10.1097/MPG.0b013e3182203caa

M3 - Article

C2 - 21519281

AN - SCOPUS:80053649658

VL - 53

SP - 404

EP - 408

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 4

ER -